A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120–CD4 protein–protein interactions
Authors:
- Fabrizio ManettiFabrizio Manetti
- José A. EstéJEJosé A. Esté
- Maurizio BottaMBMaurizio Botta
- 1 November 2009
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (21) , 6087-6091
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Small-Molecule CD4 Mimics Interact with a Highly Conserved Pocket on HIV-1 gp120Structure, 2008
- HIV entry inhibitorsThe Lancet, 2007
- Envelope Conformational Changes Induced by Human Immunodeficiency Virus Type 1 Attachment Inhibitors Prevent CD4 Binding and Downstream Entry EventsJournal of Virology, 2006
- Advances in HIV-1 Entry Inhibitors: Strategies to Interfere with Receptor and CoReceptor EngagementCurrent Pharmaceutical Design, 2006
- Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptorExpert Opinion on Investigational Drugs, 2005
- Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4Virology, 2005
- Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteinsProceedings of the National Academy of Sciences, 2004
- Biochemical and Genetic Characterizations of a Novel Human Immunodeficiency Virus Type 1 Inhibitor That Blocks gp120-CD4 InteractionsJournal of Virology, 2003
- A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor bindingProceedings of the National Academy of Sciences, 2003
- Protein–protein interactions as targets for antiviral chemotherapyReviews in Medical Virology, 2002